Opinion - The adult human brain in preclinical drug development
Opinion - The adult human brain in preclinical drug development
复制标题
DOI：
10.1038/nrd2617
复制
发表时间：
2008-08-01
影响因子：
120.1
通讯作者：
Dragunow, Mike
中科院分区：
文献类型：
--
作者：
Dragunow, Mike
神经退行性疾病是由脑细胞的死亡和功能障碍引起的，但是尽管世界范围内做出了巨大的努力，目前还没有减缓细胞死亡的神经保护性治疗方法。在临床上，从动物模型到人类的翻译失败是由于许多因素，包括物种差异，人脑复杂性，年龄，患者变异性和疾病特异性表型。因此，需要额外的方法来克服神经保护药物开发中的这些障碍。使用人脑组织微阵列筛选和在早期临床前阶段直接进行人脑细胞测试来分离保护人脑的分子来进行靶点验证可能是一种有效的策略。
Neurodegenerative disorders are caused by the death and dysfunction of brain cells, but despite a huge worldwide effort, no neuroprotective treatments that slow cell death currently exist. The failure of translation from animal models to humans in the clinic is due to many factors including species differences, human brain complexity, age, patient variability and disease-specific phenotypes. Additional methods are therefore required to overcome these obstacles in neuroprotective drug development. Incorporating target validation using human brain-tissue microarray screening and direct human brain-cell testing at an early preclinical stage to isolate molecules that protect the human brain may be an effective strategy.